news New bioinformatics tool accurately tracks synthetic DNA 1 March 2021 | By Victoria Rees (Drug Target Review) A team has demonstrated that their bioinformatics approach, PlasmidHawk, can analyse DNA sequences to identify the source of engineered plasmids.
news Novel class of non-addictive analgesics demonstrate safety in animals 7 July 2020 | By Hannah Balfour (Drug Target Review) To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen.
news European Patent Office reports increase in life science patent filings in 2019 12 March 2020 | By Victoria Rees (Drug Target Review) Last year, the European Patent Office (EPO) saw the number of patents filed in the pharmaceutical and biotechnology sectors rise for the third year in a row.
news Enhancing the speed of atomic force microscopy for biological samples 6 March 2020 | By Hannah Balfour (Drug Target Review) Researchers have applied for a patent for their innovative cantilever and vibrating plate technique which they say could increase the speed of atomic force microscopy on fragile samples.
news European patent upheld for foundational CRISPR-Cas9 intellectual property 18 February 2020 | By Victoria Rees (Drug Target Review) Arguments filed in opposition to a patent for foundation CRISPR-Cas9 intellectual property have been broadly rejected by the European Patents Office.
news Dispute over patent rights to CRISPR-Cas9 renewed by patent office 27 June 2019 | By Drug Target Review The patent office has declared an interference between 10 University of California (UC) patent applications.
article Drug patents expire. Can IP data help you prepare? 26 October 2017 | By Ali Hussein When important and valuable patents expire, some rejoice and some dismay. Usually, after 20 years of protection, a masterpiece becomes available to all to reproduce, at the loss of the former patent owner...
news Celyad gets patent for TCR-deficient CAR T-cell method 2 March 2016 | By Victoria White The US Patent 9,273,283 is the second patent of Celyad allogeneic intellectual property portfolio that is awarded by the USPTO...
article When 0.77% is greater than 1%: salutatory lessons from the Court of Appeal 21 September 2015 | By Jacob Gifford Head (Thomas More Chambers) All new drugs rely, to a greater or lesser extent, on pre-existing research and development. Much of this pre-existing research will have resulted in patented methods and products. A major challenge for all researchers is therefore to develop new drugs which do not infringe other company’s patents.
news Domainex granted US and EU patents for its lead programme, targeting IKK epsilon and TBK1 11 May 2015 | By Victoria White US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
news Cardio3 BioSciences receives Notice of Allowance for first U.S. patent broadly covering TCR-deficient T-Cells engineered to express a chimeric antigen receptor 8 April 2015 | By Victoria White Cardio3 has received a Notice of Allowance from the USPTO for a patent application covering TCR-deficient T-Cells which are engineered to express a CAR...
news Key TxCell patent to be granted in the US for its lead product Ovasave(R) 18 March 2015 | By Victoria White TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
news Key bioelectronic medical patent for cancer treatment issued by the U.S. Patent & Trademark Office 11 February 2015 | By Cancer-Code Corporation Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
news SciFluor Life Sciences awarded U.S. Patent for KCNQ2/3 activator designed for treatment of epilepsy and related neurological disorders 8 January 2015 | By SciFluor Life Sciences SciFluor Life Sciences, LLC, an emerging clinical stage biopharmaceutical company that creates innovative therapeutics for patients with ophthalmologic and neurologic disease, announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,916,133 with claims covering the novel compound SF0034...
news Key US patents granted for GPCR-focused drug discovery platform arising from pioneering research and translational expertise at MRC and MRC Technology 17 December 2014 | By MRC Technology Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
